Description

Selumetinib is a potent and highly selective small-molecule inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2), a key component of the RAS/MAPK signaling pathway. This targeted therapeutic agent is crucial for the research and development of novel oncology treatments, particularly for cancers driven by mutations in this pathway. It is primarily utilized by pharmaceutical R&D teams, contract research organizations (CROs), and academic institutions engaged in preclinical and clinical-stage cancer research.

Application

• Oncology Research & Drug Development: A critical reference standard and active pharmaceutical ingredient (API) in the development of targeted cancer therapies.
• Preclinical Studies: Used in in vitro and in vivo models to investigate the efficacy of MEK inhibition against various tumor types, including non-small cell lung cancer (NSCLC), melanoma, and neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas.
• Mechanism of Action (MoA) Studies: Employed to elucidate the downstream effects of RAS/MAPK pathway blockade on cell proliferation, survival, and differentiation.
• Combination Therapy Research: Investigated in combination with other chemotherapeutic agents or targeted inhibitors (e.g., BRAF inhibitors) to overcome drug resistance and improve therapeutic outcomes.
• Formulation Development: Serves as the core component in the development of various dosage forms, such as capsules or tablets, for clinical use.
• Biochemical Assay Development: Used as a control compound in high-throughput screening (HTS) and enzymatic assays to identify and validate new MEK inhibitors.

Basic Information

Product Name	Selumetinib
CAS No.	606143-52-6
Molecular Formula	C17H15BrClFN4O3
Molecular Weight	457.68 g/mol
Synonyms	AZD6244; ARRY-142886; 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; N-[(2S)-2,3-Dihydroxypropyl]-5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxamide (discontinued isomer); Selumetinib free base
EINECS	Contact for details

Quality Control

Our Selumetinib is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, residual solvent analysis, and identification by spectroscopic methods (IR, NMR, MS), to ensure it meets stringent specifications for research and development use. Certificates of Analysis (COA) with detailed batch-specific data are available upon request to support your regulatory and quality documentation needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under anhydrous conditions. For long-term storage, consider desiccants or an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥98.0%
Water Content (KF)	≤0.5%
Residual Solvents (GC)	Meets ICH Q3C guidelines
Heavy Metals	≤20 ppm
Assay (on dried basis)	97.0% - 103.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.